Revenue: As of FY2026 Q1, the actual value is USD 0.EPS: As of FY2026 Q1, the actual value is USD -0.58.EBIT: As of FY2026 Q1, the actual value is USD -2.65 M.<h4>Financial Position</h4>Kiora Pharmaceuticals, Inc. reported cash and cash equivalents of $10,955,359 at March 31, 2026, an increase from $8,696,570 at December 31, 2025. Short-term investments decreased to $2,916,701 at March 31, 2026, from $8,392,513 at December 31, 2025. Collaboration receivables were $1,544,253 and tax and other receivables were $1,906,923 as of March 31, 2026. Total current assets decreased to $18,682,848 from $21,748,448 at December 31, 2025. Total assets were $21,227,089 as of March 31, 2026, down from $24,253,300 at December 31, 2025. Total current liabilities decreased to $2,798,264 from $3,631,498 in the prior quarter. Total liabilities were $7,292,528 compared to $8,126,764 at December 31, 2025. Total stockholders’ equity was $13,934,561 as of March 31, 2026, a decrease from $16,126,536 at December 31, 2025. Subsequent to the quarter end, Kiora Pharmaceuticals, Inc. raised an additional $5.0 million in gross proceeds from a strategic equity investment.<h4>Operating Expenses</h4>Research and development expenses were $2,123,725 for the three months ended March 31, 2026, before recognizing $1,233,224 in collaboration credits, compared to $2,531,887 in R&amp;D expenses and $1,966,123 in collaboration credits for the same period in 2025. General and administrative expenses for the first quarter of 2026 were $1,612,267, up from $1,489,398 in the first quarter of 2025. The change in fair value of contingent consideration was $7,427 for the quarter, significantly lower than $275,192 in the prior-year period. Total operating expenses for the first quarter of 2026 were $2,510,195, an increase from $2,330,354 in the first quarter of 2025.<h4>Operating Loss and Net Loss</h4>Kiora Pharmaceuticals, Inc. reported an operating loss of -$2,510,195 for the first quarter of 2026, compared to -$2,330,354 for the first quarter of 2025. Net interest income was $139,338, down from $276,633 in the prior-year period, and other expense, net, was -$47,127, compared to -$16,253 in the first quarter of 2025. The net loss for the first quarter of 2026 was -$2,417,984, compared to -$2,192,980 for the first quarter of 2025. Basic and diluted net loss per common share was -$0.58 for the first quarter of 2026, compared to -$0.52 for the first quarter of 2025. The comprehensive loss for the quarter was -$2,400,643, compared to -$2,208,007 in the prior year.<h4>Operational Highlights</h4>Enrollment in the Phase 2 ABACUS-2 study for KIO-301 is active, with recruitment nearing 50% completion and clinical trial site expansion underway. Results from the ABACUS-1 clinical trial for KIO-301 were published in Nature Medicine, validating its potential for vision restoration. The Phase 2 KLARITY study for KIO-104 is progressing, with a safety review anticipated to support advancement to a higher dose level.<h4>Outlook / Guidance</h4>Kiora Pharmaceuticals, Inc. projects an operational runway extending into late 2028, supported by current cash, anticipated collaboration reimbursements, and additional capital raised post-quarter end. This runway is expected to last beyond the projected clinical data readouts from its ongoing clinical trials, providing strategic flexibility. The company is expanding trial sites for ABACUS-2 and preparing for potential future global registration studies and commercial launch for KIO-301, while also advancing KIO-104 development.

Kiora Pharmaceuticals | 8-K: FY2026 Q1 Revenue: USD 0